Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Avoid Companhia Brasileira de Distrib. (ADR) (CBD)?

Page 1 of 2

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile gigantic failures like hedge funds’ recent losses in Valeant. Let’s take a closer look at what the funds we track think about Companhia Brasileira de Distrib. (ADR) (NYSE:CBD) in this article.

Is Companhia Brasileira de Distrib. (ADR) (NYSE:CBD) an attractive investment today? Money managers are getting less optimistic. The number of bullish hedge fund bets shrunk by 1 recently. CBD was in 8 hedge funds’ portfolios at the end of the third quarter of 2015. There were 9 hedge funds in our database with CBD positions at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Radian Group Inc (NYSE:RDN), Corelogic Inc (NYSE:CLGX), and ENSCO PLC (NYSE:ESV) to gather more data points.

Follow Companhia Brasileira De Dist (NYSE:CBD)
Trade (NYSE:CBD) Now!

According to most shareholders, hedge funds are assumed to be worthless, old investment vehicles of the past. While there are greater than 8000 funds with their doors open at present, We choose to focus on the elite of this group, about 700 funds. Most estimates calculate that this group of people manage the lion’s share of the smart money’s total asset base, and by tracking their unrivaled investments, Insider Monkey has discovered a few investment strategies that have historically outpaced the broader indices. Insider Monkey’s small-cap hedge fund strategy surpassed the S&P 500 index by 12 percentage points per annum for a decade in their back tests.

With all of this in mind, let’s take a gander at the fresh action surrounding Companhia Brasileira de Distrib. (ADR) (NYSE:CBD).

What have hedge funds been doing with Companhia Brasileira de Distrib. (ADR) (NYSE:CBD)?

At the end of the third quarter, a total of 8 of the hedge funds tracked by Insider Monkey held long positions in this stock, a decline of 11% from the previous quarter. With the smart money’s sentiment swirling, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their holdings significantly (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Ken Fisher’s Fisher Asset Management has the largest position in Companhia Brasileira de Distrib. (ADR) (NYSE:CBD), worth close to $16 million, corresponding to less than 0.1% of its total 13F portfolio. The second largest stake is held by AQR Capital Management, led by Cliff Asness, holding an $4.5 million position; less than 0.1% of its 13F portfolio is allocated to the stock. Remaining hedge funds and institutional investors that are bullish comprise Jim Simons’s Renaissance Technologies, Israel Englander’s Millennium Management and Glenn Russell Dubin’s Highbridge Capital Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!